Immunome (IMNM) – Research Analysts’ Weekly Ratings Updates

A number of firms have modified their ratings and price targets on shares of Immunome (NASDAQ: IMNM) recently:

• 5/30/2026 – Immunome was downgraded by Wall Street Zen from “hold” to “sell”.
• 5/28/2026 – Immunome had its price target raised by Truist Financial Corporation from $36.00 to $37.00. They now have a “buy” rating on the stock.
• 5/28/2026 – Immunome is now covered by Barclays PLC. They set an “overweight” rating and a $36.00 price target on the stock.
• 5/28/2026 – Immunome is now covered by Barclays PLC. They set an “overweight” rating and a $36.00 price target on the stock.
• 5/16/2026 – Immunome was upgraded by Wall Street Zen from “sell” to “hold”.
• 5/15/2026 – Immunome had its price target lowered by Leerink Partners from $37.00 to $33.00. They now have an “outperform” rating on the stock.
• 5/13/2026 – Immunome had its “buy” rating reaffirmed by HC Wainwright. They now have a $40.00 price target on the stock.
• 5/4/2026 – Immunome was upgraded by Truist Financial Corporation to “strong-buy”.
• 4/21/2026 – Immunome had its “sell (d-)” rating reaffirmed by Weiss Ratings.

Insiders Place Their Bets

In other Immunome news, insider Jack Higgins sold 9,438 shares of Immunome stock in a transaction dated Thursday, April 2nd. The stock was sold at an average price of $21.64, for a total transaction of $204,238.32. Following the transaction, the insider directly owned 22,000 shares in the company, valued at approximately $476,080. The trade was a 30.02% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Jean Jacques Bienaime bought 10,500 shares of Immunome stock in a transaction on Friday, June 5th. The shares were acquired at an average price of $19.45 per share, for a total transaction of $204,225.00. Following the completion of the acquisition, the director owned 43,415 shares of the company’s stock, valued at approximately $844,421.75. This represents a 31.90% increase in their position. The disclosure for this purchase is available in the SEC filing. In the last ninety days, insiders have sold 139,438 shares of company stock valued at $2,964,664. Insiders own 7.21% of the company’s stock.

Immunome, Inc is a clinical-stage biotechnology company focused on discovering and developing novel antibody-based therapeutics for oncology and infectious diseases. The company leverages a proprietary platform that mines the natural B-cell repertoire of patients with active disease to identify fully human monoclonal antibodies with unique mechanisms of action. Immunome’s approach is designed to uncover antibodies that engage the immune system in ways that traditional discovery methods may miss, enabling the development of therapies with potential for improved efficacy and safety profiles.

The company’s lead oncology program, IMM-BCP-01, is a multi-antibody cocktail currently in early-stage clinical trials targeting breast cancer antigens.